1 BioSpectrum | www.BioSpectrumAsia.

com | A CyberMedia Publication

Fastest 50
Rank Company Country
Revenue
CY 2012
Revenue
CY 2011
Revenue
CY 2010
Revenue
CY 2009
Revenue
CY 2008
% Growth
over 2011
1
Huapont-Nutrichem (formerly
Chongqing Huapont Pharm)
China 618.30 105.52 80.43 79.68 84.24 485.96
2 Bionomics Australia 13.80 4.12 4.04 3.20 3.03 234.95
3 Taiwan Liposome Company Taiwan 7.22 2.35 - - - 207.68
4 Cordlife Singapore 9.56 3.51 23.44 19.42 13.13 172.36
5 Living Cell Technologies
Australia/New
Zealand
6.29 2.47 2.26 - - 154.48
6 Apeloa Company China 556.82 245.52 - 196.92 - 126.79
7 Acrux Australia 11.22 5.15 135.22 1.36 2.72 117.86
8 Nanosonics Australia 12.68 5.98 1.73 0.89 1.33 112.06
9 Universal Biosensors Australia 30.70 15.15 16.85 17.46 2.48 102.64
10 Guilin Layn Natural Ingredients* China 38.70 19.81 60.25 16.64 - 95.36
11 Pharmaxis Australia 2.16 1.13 5.06 3.81 8.04 90.95
12 Genetic Technologies Australia 3.65 2.06 14.24 8.29 9.25 77.20
13
Nantong Jinghua
Pharmaceutical
China 106.43 60.08 40.52 37.96 34.37 77.15
14 Medy-Tox South Korea 32.50 19.53 18.45 13.75 8.08 66.41
15 Beijing SL Pharmaceutical China 161.20 99.65 67.62 52.90 - 61.77
16 Austofix Australia 2.00 1.24 - - - 61.23
17 Cyclopharm Australia 11.10 7.11 8.80 10.77 7.76 56.12
18
Allied Overseas (Quality
HealthCare Asia)
China 27.17 17.43 13.00 - - 55.85
19 Guangzhou Pharmaceutical China 1316.66 870.34 650.38 556.40 517.22 51.28
20 Allied Biotech Taiwan 16.10 10.67 - - - 50.83
21 Concord Medical Services China 107.54 72.02 57.53 42.27 32.85 49.31
22 Hua Han Bio-Pharmaceutical China 224.25 150.49 104.07 134.52 30.99 49.01
23 Vita Life Sciences Australia 37.23 25.15 - - - 48.04
24 Tianjin Lisheng Pharmaceutical China 178.91 122.18 109.01 87.17 86.70 46.43
25 OK Biotech Taiwan 22.00 15.19 - - - 44.84
* Q4 Revenue extrapolated/estimated due to non-availability of data (Revenue in million $)
These 50 companies contributed $31 billion
to the $86.87 billion total revenue of publicly
listed companies
Asias leading company Sinopharm made it to
the list at No. 46, clocking a growth of over
30 percent
Australia and New Zealand had 15 companies
in the list, same number as China. India made
it to the list with 10 companies
Asias
Fastest
Fastest 50 Bioscience Companies in Asia - 2012 (By % Growth)
A CyberMedia Publication | www.BioSpectrumAsia.com | BioSpectrum 2
Asias
Fastest
Fastest 50 Bioscience Companies in Asia - 2012 (By % Growth)
Rank Company Country
Revenue
CY 2012
Revenue
CY 2011
Revenue
CY 2010
Revenue
CY 2009
Revenue
CY 2008
% Growth
over 2011
26 Sino Biopharmaceutical China 1082.80 751.92 525.88 425.24 306.74 44.00
27
Shandong Wohua
Pharmaceutical
China 33.54 23.81 13.43 25.20 28.15 40.85
28 SciVision Biotech Taiwan 6.02 4.30 - 0.47 0.18 39.89
29 Biota Holdings Australia 24.20 17.32 16.54 88.30 38.24 39.72
30 Dr Chip Biotechnology Taiwan 1.40 1.01 - 2.87 1.79 38.95
31 Ajanta Pharma India 153.17 111.04 97.07 75.36 65.63 37.94
32 Arvind Remedies India 119.09 86.47 77.04 55.84 42.68 37.72
33 Aarti Drugs India 161.29 118.22 107.77 94.98 128.40 36.44
34 Macrogen* South Korea 39.72 29.14 20.26 9.20 13.16 36.30
35 Neuren Pharmaceuticals
Australia/New
Zealand
4.50 3.31 4.80 3.94 2.04 35.95
36 Glenmark Pharmaceuticals India 383.94 282.71 260.14 205.67 221.62 35.81
37 Sihuan Pharmaceutical China 486.80 358.73 - - - 35.70
38 Lupin India 1395.47 1028.78 929.84 725.31 645.51 35.64
39 Fisher & Paykel Healthcare Australia 548.07 404.09 - - - 35.63
40 Aarey Drugs India 32.50 23.97 12.89 6.70 6.21 35.60
41 Heartware Australia 110.90 82.80 55.20 24.20 0.26 33.94
42 Celestial Biolabs India 5.11 3.82 5.37 5.16 3.54 33.72
43 Bloomage BioTechnology China 44.00 32.98 - - - 33.41
44 Adimmune Taiwan 11.62 8.71 - - - 33.35
45 Sagittarius Life Science Taiwan 11.34 8.53 - 8.94 1.34 32.89
46 Sinopharm China 21728.89 16355.97 10226.54 6884.09 5588.51 32.85
47 Granules India India 133.25 100.58 86.56 77.13 59.86 32.49
48 Seegene South Korea 46.30 35.46 - - - 30.57
49 Torrent Pharma India 513.62 394.20 380.20 286.65 300.22 30.29
50 Divis Laboratories India 437.81 336.99 257.41 201.34 238.85 29.92
* Q4 Revenue extrapolated/estimated due to non-availability of data (Revenue in million $)
Companies
Fastest 50
3 BioSpectrum | www.BioSpectrumAsia.com | A CyberMedia Publication
Fastest 50
CEO & MD
Dr Deborah Rathjen
Website: www.bionomics.com.au
Start-up Year: 1999
Bionomics is a drug candidate developer that
focuses on unmet clinical needs. Bionomics pipeline includes
BNC105, a vascular disrupting agent for the treatment of solid tumors,
currently in Phase II clinical trials; BNC210, which is under
development for the treatment of anxiety disorders; Kv1.3, which are
blockers to treat infammatory disorders; and Alpha 7 program for
Alzheimers disease.
$13.80 mn
R
E
V
E
N
U
E
2
A
U
S
T
R
A
L
I
A
2
BIONOMICS
General manager & director:
Mr Ming Xin Pan
Website: www.huapont.com.cn
Start-up Year: 1992
C
H
I
N
A
Huapont-Nutrichem is the fastest growing com-
pany in active pharmaceutical ingredient manufacturing for generic
markets in China and internationally. The companys Active Pharma-
ceutical Ingredient (API) products include retinoids, glucocorticoids,
dermatology, oncology products. It has achieved Japans accreditation
as foreign drug manufacturer for R&D in retinoic acids series prod-
ucts, that accounts for over 56 percent market share in China.
R
E
V
E
N
U
E
$618.30 mn
HUAPONT-NUTRICHEM
1
CEO:
Mr Yee Pinh Jeremy
Website: www.cordlifeindiacom
Start-up Year: 2001
Cordlife, stem cell banking system from cord
blood, is the frst AABB-accredited private cord blood bank in Singa-
pore and South East Asia. Cordlife has established cell banks with full
processing and cryopreservation storage facilities in Singapore and
Hong Kong, delivering services to over 7,200 families. Cord blood has
the potential to provide treatment for diseases like blood cancers such
as acute myelogenous leukaemia, and acute lymphoblastic leukemia.
$9.56 mn
R
E
V
E
N
U
E
2
S
I
N
G
A
P
O
R
E
4
CORDLIFE
CEO:
Dr Keelung Hong
Website: www.tlcbio.com
Start-up Year: 1997
T
A
I
W
A
N
The company focuses on innovative pharmaceuti-
cal products based on its proprietary drug delivery technologies. Its
strengths lie in lipid-based formulation parenteral drugs to optimize
the pharmacokinetics of drugs for better effcacy and lower toxicity.
Among other drug delivery technologies by the company is receptor-
targeted immunoliposomes for antibody-mediated intracellular deliv-
ery of therapeutics.
R
E
V
E
N
U
E
$7. 22 mn
TAIWAN LIPOSOME COMPANY
3
MD:
Ms Andrea Grant
Website: www.lctglobal.com
Start-up Year: 1987
N
E
W

Z
E
A
L
A
N
D

/

A
U
S
T
R
A
L
I
A
It is the frst company to enter clinical trials using
therapeutic porcine cell implants globally. The company has developed
Diabecell for people suffering from unstable Type 1 diabetes. Tiny Dia-
becell microspheres, containing live islet cells, are implanted into a pa-
tients abdomen using a simple laparoscopic procedure. Once implant-
ed, Diabecell works by self-regulating and effciently secreting insulin
and glucagon in response to the patients changing glucose levels.
R
E
V
E
N
U
E
$6.29 mn
LIVING CELL TECHNOLOGIES
5
486%
235%
208%
172%
154%
B
i
o
S
p
e
c
t
r
u
m

A
s
i
a

F
a
s
t
e
s
t

5
0

L
i
s
t

2
0
1
3
A CyberMedia Publication | www.BioSpectrumAsia.com | BioSpectrum 4
Executive chairman:
Mr Ross Dobinson BBus
Website: www.acrux.com.au
Start-up Year: 1992
Acrux provides pharmaceutical products using in-
novative, patented technology to administer drugs through the skin.
It has developed fast drying, non-occlusive topical sprays for an en-
hanced transdermal delivery platform with low or no skin irritation,
superior cosmetic acceptability, and simple, accurate and fexible dos-
ing. Acrux earns revenue from its products through licensees in the
global market.
$11.22 mn
R
E
V
E
N
U
E
2
A
U
S
T
R
A
L
I
A
7
ACRUX
Chairman:
Xu Wencai
Website: www.apeloa.com
C
H
I
N
A
Apeloa Kangyu is engaged in R&D, manufactur-
ing and marketing of APIs, formulations and veterinary drugs. It also
supplies high quality chemical synthesis as well as biological synthe-
sis products. Apeloa Kangyu owns two GMP certifed and the US FDA
approved facilities, and have passed OSHAS18001, ISO14001 and
ISO9001 certifcations. Nearly 50 percent of its products are sold to
over 32 countries and regions in Asia, Europe and the US.
R
E
V
E
N
U
E
$556.82 mn
APELOA KANGYU
6
CEO:
Mr Paul Wright
Website: www.universalbiosensors.com
Start-up Year: 2001
Universal Biosensors has developed OneTouch
Verio blood glucose test strips, a blood glucose monitoring product
commercialized globally by LifeScan, a Johnson & Johnson company.
Using a tiny fnger prick blood sample, OneTouch Verio enables in-
stant readings of blood glucose levels. The company is now developing
Prothrombin Time, a test to monitor the effect of the blood thinning
anticoagulant warfarin, using its electrochemical cell technology.
$30.70 mn
R
E
V
E
N
U
E
2
A
U
S
T
R
A
L
I
A
9
UNIVERSAL BIOSENSORS
CEO & MD:
Mr Ron Weinberger
Website: www.nanosonics.com.au
Start-up Year: 2001
A
U
S
T
R
A
L
I
A
It has developed Trophon, a next generation ultra-
sound probe disinfection system, to fght healthcare acquired infections
(HAI). The technology produces a proprietary disinfectant containing
sub-micron mist which can be quickly distributed to surfaces requir-
ing disinfection or sterilization. The Center for Disease Control and
Prevention estimates that as many as two million people suffer from
HAIs annually in the US, resulting in more than 100,000 deaths.
R
E
V
E
N
U
E
$12.68 mn
NANOSONICS
8
General manager:
Mr Xin De Yao
Website: www.layncorp.com
Start-up Year: 1995
C
H
I
N
A
Guilin Layn Natural Ingredients is focused on
identifcation, development and production of active principles derived
from plants that are traditionally recognized as having therapeutic
properties, with application in the food and beverage, nutrition, health
and personal care industries. Layn has invested in new manufacturing
facility with 16 state-of-the-art, fully computer controlled cGMP extrac-
tion lines for a total capacity of 15,000MT raw material annually.
R
E
V
E
N
U
E
$38. 70 mn
GUILIN LAYN NATURAL INGREDIENTS
10
127%
118%
112%
103%
95%
Fastest 50
B
i
o
S
p
e
c
t
r
u
m

A
s
i
a

F
a
s
t
e
s
t

5
0

L
i
s
t

2
0
1
3
5 BioSpectrum | www.BioSpectrumAsia.com | A CyberMedia Publication
Fastest 50
CEO:
Ms Alison J Mew
Website: www.gtglabs.com
Genetic Technologies, a genetic diagnostics com-
pany with access to over 2000 different genetic tests, has developed
BREVAGen, a test that looks for the presence (or absence) of genetic
variations in womens DNA known as Single Nucleotide Polymor-
phisms, or SNPs. The test identifes changes in DNA to either confrm
a diagnosis of a specifc disorder of which a person displays signs or
symptoms, or to identify individuals at risk of developing a disease.
$3.65 mn
R
E
V
E
N
U
E
2
A
U
S
T
R
A
L
I
A
12
GENETIC TECHNOLOGIES
CEO:
Mr Gary Phillips
Website: www.pharmaxis.com.au
Start-up Year: 1998
A
U
S
T
R
A
L
I
A
Pharmaxis has developed Aridol, a drug designed
to identify hyper-responsive airways and to assist in diagnosing and
managing asthma. Aridol is approved for sale in Australia, major Eu-
ropean countries, South Korea and the US. Pharmaxiss another prod-
uct Bronchitol is designed to restore normal lung hydration, improve
lung function and help relieve the mucus burden in the lungs of pa-
tients suffering from chronic respiratory conditions.
R
E
V
E
N
U
E
$2.16 mn
PHARMAXIS
11
CEO:
Mr Jung Hyun-Ho
Website: www.medytox.com
Start-up Year: 2000
Medy-Tox researches, develops and manufactures
biopharmaceutical products using clostridium botulinum, a micro-
organism toxin known as botox, widely used for treating ophthalmic
diseases, endocrine diseases, digestive systems, neurological diseases,
urology systems, and beauty treatments. Medytox has received Aus-
tralias TGA approval in phase II clinical trial of next generation botu-
linum toxin.
$32.50 mn
R
E
V
E
N
U
E
2 14
MEDY-TOX
Chairman & president:
Mr Zhu Chunlin
Website: www.ntjhzy.com/en
Start-up Year: 2002
C
H
I
N
A
Nantong Jinghua Pharmaceutical is a dominant
enterprise in pharmaceutical research, development and manufacture
of APIs, intermediates, formulations, and traditional Chinese medi-
cines. Main APIs by the company include Phenobarbital, Primidone,
5-Fluorouracil, 5-Flucytosine, Phenylbutazone, Piroxicam, Aminoglu-
tethimide, Tenoxicam, Propylthiouracil, Moxonidine HCl and their
intermediates and derivatives.
R
E
V
E
N
U
E
$106.43 mn
NANTONG JINGHUA PHARMACEUTICAL
13
CEO:
Mr Ming Bo Xu
Website: www.slpharm.com.cn
Start-up Year: 1994
C
H
I
N
A
Beijing SL Pharmaceutical develops and markets
gene engineering drugs like Li Sheng Su, a recombinant human granu-
locyte colony-stimulating factor for injection for treating neutropenia;
Mai Ge Er, a recombinant human interleukin-11, for injection to treat
thrombocytopenia; and Xin Ji Er, a recombinant human 125Ala in-
terleukin-2, for injection for various indications such as renal cancer,
melanoma, and malignant pleural effusion.
R
E
V
E
N
U
E
$161.20 mn
BEIJING SL PHARMACEUTICAL
15
91%
77%
77%
66%
62%
B
i
o
S
p
e
c
t
r
u
m

A
s
i
a

F
a
s
t
e
s
t

5
0

L
i
s
t

2
0
1
3
S
O
U
T
H

K
O
R
E
A
A CyberMedia Publication | www.BioSpectrumAsia.com | BioSpectrum 6
MD & CEO:
Mr James McBrayer
Website: www.cyclopharm.com/au
Start-up Year: 1984
Radiopharmaceutical company Cyclopharm has
developed Technegas technology that emits gas-like substance which
is inhaled by the patient via a breathing apparatus, which then allows
multiple views and tomography imaging under a gamma or single pho-
ton emission computed tomography camera for the superior diagnosis
of pulmonary emboli (blood clots in the lungs).
$11.10 mn
R
E
V
E
N
U
E
2
A
U
S
T
R
A
L
I
A
17
CYCLOPHARM
Executive chairman:
Mr Mark Balnaves
Website: www.austofx.com.au
A
U
S
T
R
A
L
I
A
Austofx manufactures and designs medical devic-
es and implants for the feld of Orthopaedics - the surgical specializa-
tion concerned with the musculoskeletal system. Austofx has devel-
oped Tectona Hip Plate for hip fractures, Volar Radius Plate for use in
the treatment for fractures of the distal radius, intramedullary nail for
fxation of up to four part fractures of the proximal humerus, as well as
fractures of the humeral shaft.
R
E
V
E
N
U
E
$2 mn
AUSTOFIX
16
CEO:
Mr Yang Rongming
Website: www.gzmpc.com
Start-up Year: 1951
The company engages in a combination of sci-
entifc research and production of pharmaceuticals, and traditional
Chinese medicines. The company has invested on technological inno-
vation system and has launched post-doctoral research programs. It
has its own research and development center for key pharmaceutical
projects. Its products such as no sugar as well as low sugar herbal tea
beverages have recorded greater increase in sales revenue in 2012.
$1316.60 mn
R
E
V
E
N
U
E
2
C
H
I
N
A
19
GUANGZHOU PHARMACEUTICAL
CEO:
Mr Mark Wong Tai Chun
Website: www.alliedoverseas.com.hk
C
H
I
N
A
Allied Overseas provides elderly care services and
distribution of medical equipment in Hong Kong. It offers specialized
care programs to ft individuals physical, social, psychological, and re-
habilitation requirements; special treatments; and dementia and para-
medical services, as well as infrmary services. It operates four elderly
care homes and is involved in the distribution of medical equipment to
hospitals, medical centers, and other healthcare facilities.
R
E
V
E
N
U
E
$27. 17 mn
ALLIED OVERSEAS
18
CEO:
Mr Qing Hui Lin
Website: www.altratene.com
Start-up Year: 2002
T
A
I
W
A
N
Allied Biotech is one of the leading manufactur-
ers of carotenoids, which are marketed worldwide under the name
Altratene. Its products include Beta-carotene, a color pigment that is
used to impart color to food, beverage, pharmaceutical, and cosmetic
products; Beta-Apo-8, red color, which is used as a food colorant; Co-
enzyme Q10, a coenzyme located in the mitochondria throughout the
body; and Lycopene, a physiological antioxidant.
R
E
V
E
N
U
E
$16.10 mn
ALLIED BIOTECH
20
61%
56%
56%
51%
51%
Fastest 50
B
i
o
S
p
e
c
t
r
u
m

A
s
i
a

F
a
s
t
e
s
t

5
0

L
i
s
t

2
0
1
3
7 BioSpectrum | www.BioSpectrumAsia.com | A CyberMedia Publication
Fastest 50
CEO:
Ms Jie Deng
Website: www.huahanbp.com.hk
Start-up Year: 1992
The company is engaged in research, develop-
ment, production and distribution of a range of herbal-based gyneco-
logical medicines and bio-pharmaceutical products. It primarily offers
prescription drugs, including the Yeosure series of gynecological anti-
infammatory products, Camptothecine series of anti-tumor products
like Paclitaxel Injection, Xinshenghua Keli, an endocrine product, and
Cefadroxil Granules, an anti-infammatory product for infants.
$224. 25 mn
R
E
V
E
N
U
E
2
C
H
I
N
A
22
HUA HAN BIO-PHARMACEUTICAL
CEO:
Mr Jianyu Yang
Website: www.cmsholdings.com
Start-up Year: 2009
C
H
I
N
A
Concord Medical Services owns and operates a
network of radiotherapy and diagnostic imaging centers throughout
China. It provides support to its network of radiotherapy and diagnos-
tic imaging centers. Prior to setting up new centers, it also arranges
training for medical professionals and invites experts from academic
or professional institutions to provide guidance in latest radiotherapy
treatments.
R
E
V
E
N
U
E
$107. 54 mn
CONCORD MEDICAL SERVICES
21
Chairman/President:
Mr Sun Baowei
Website: www.lishengpharma.com
Start-up Year: 1951
Focusing primarily on manufacturing and market-
ing chemical drugs in China, Tianjin Lisheng Pharmaceutical provides
drugs for cardio and cerebral vascular systems, anti-infection drugs,
and hormone drugs. It offers drugs in the form of tablets, hard cap-
sules, pills, free-dry powder injections, and water injections, as well
as raw drugs. Tianjin Lisheng exports its products to Japan, Australia,
South Korea, Europe, the Americas, and the South East Asia.
$178.91 mn
R
E
V
E
N
U
E
2
C
H
I
N
A
24
TIANJIN LISHENG PHARMACEUTICAL
MD:
Mr Lim Sung (Eddie) Tie
Website: www.vitalifesciences.com
Start-up Year: 1947
A
U
S
T
R
A
L
I
A
Pharmaceutical and healthcare company Vita Life
Sciences is developing wide range of supplements, vitamins, minerals,
meal replacement, sports nutrition, and herbals for men, women and
children under brand name Herbs of Gold and VitaScience in Austra-
lia, and VitaHealth, VitaLife and Pharma Direct in rest of Asia. Prod-
ucts developed by the company comply with the respective countries
rules and regulations such as the DCA, FDA and TGA.
R
E
V
E
N
U
E
$37. 23 mn
VITA LIFE SCIENCES
23
MD:
Mr Jia De Lai
Website: www.okbiotech.com
Start-up Year: 2005
T
A
I
W
A
N
Being one of the leading manufacturers of glucose
meters, OK Biotech is known to develop quick response, reliable and
stable products for diabetes patients. It develops blood glucose moni-
toring systems with its brand Okmeter. The leading products by this
company include Optima, Match, Link and Direct blood glucose me-
ters. OK Biotech products are distributed worldwide. OK Biotech also
provides professional OEM/ODM/contract manufacturing services.
R
E
V
E
N
U
E
$22 mn
OK BIOTECH
25
49%
49%
48%
46%
45%
B
i
o
S
p
e
c
t
r
u
m

A
s
i
a

F
a
s
t
e
s
t

5
0

L
i
s
t

2
0
1
3
A CyberMedia Publication | www.BioSpectrumAsia.com | BioSpectrum 8
President:
Mr Zhang Ge
Website: www.wohua.cn
Start-up Year: 1959
The company is an industry leader in developing,
producing and selling Chinese herbal medicines for cardio-cerebral
diseases. The companys primary products are Xinkeshu tablets and
capsules for the treatment of coronary heart disease; Naoxueshu Oral
Liquid, which promotes blood circulation by removing blood stasis;
Hupo Xiaoshi granules for the treatment of urethral calculus; and Yu-
andu granules to treat infuenza.
$33.54 mn
R
E
V
E
N
U
E
2
C
H
I
N
A
27
SHANDONG WOHUA PHARMACEUTICAL
Chairman/Founder:
Mr Tse Ping
Website: www.sinobiopharm.com
Start-up Year: 2000
C
H
I
N
A
For over a decade, Sino Biopharmaceuticals has
developed and marketed biopharmaceutical products for the medi-
cal treatment of ophthalmia. The company also produces modernized
Chinese medicine and chemical medicine for the treatment of liver
diseases, cardiovascular and cerebrovascular diseases, geriatric and
hepatitis. Sino Biopharmaceuticals is currently developing therapy
drugs for cancer, analgesic and respiratory diseases.
R
E
V
E
N
U
E
$1082.80 mn
SINO BIOPHARMACEUTICAL
26
CEO & MD:
Peter Cook
Website: www.biotapharma.com
This company focuses on the discovery and devel-
opment of anti-infective products to prevent and treat serious and po-
tentially life-threatening infectious diseases. Biota has discovered two
generations of neuraminidase inhibitors (NIs) that have been com-
mercialized, the frst of which is zanamivir, marketed worldwide as
Relenza by GlaxoSmithKline.
$24.20 mn
R
E
V
E
N
U
E
2
A
U
S
T
R
A
L
I
A
29
BIOTA
Chairman:
Mr Kaicheng Han
Website: www.scivision.com.tw
Start-up Year: 2001
T
A
I
W
A
N
Known as the only company in Taiwan to mass
produce Hyaluronic Acid by fermentation biotechnology, SciVision
Biotech uses a self-owned genetic transfer technique. The company
has successfully developed a non-traditional microbial fermentation
technique to produce medical grade Hyaluronic Acid (HA) with high
quality and high safety. It manufactures and distributes hyaluronic
acid medical equipment.
R
E
V
E
N
U
E
$6.02 mn
SCIVISION BIOTECH
28
CEO:
Mr Shin-Hwan Wang
Website: www.biochipnet.com
Start-up Year: 1998
T
A
I
W
A
N
Engaged primarily in research, development,
manufacture and distribution of biological products and testing de-
vices, Dr Chip Biotechnology also provides detection services, technol-
ogy transfer, and consulting services. Dr Chip Biotechnology provides
DNA/RNA sample preparation kits, polymersac chain reaction kits,
rapid hybridization equipment, biochips, testing agents, biological
preparations, as well as components of biological testing equipment.
R
E
V
E
N
U
E
$1.40 mn
DR CHIP BIOTECHNOLOGY
30
44%
41%
40%
40%
39%
Fastest 50
B
i
o
S
p
e
c
t
r
u
m

A
s
i
a

F
a
s
t
e
s
t

5
0

L
i
s
t

2
0
1
3
9 BioSpectrum | www.BioSpectrumAsia.com | A CyberMedia Publication
Fastest 50
S
O
U
T
H


K
O
R
E
A
CEO & MD:
Mr B Arvind Shah
Website: www.arvindremedies.com
Start-up Year: 1988
The company manufactures and markets allopath-
ic and ayurvedic pharmaceutical products for local as well as interna-
tional markets. Increasing its production capacity, product categories,
market share, advancements in R&D, market reach and global accep-
tance, the company has managed to get a strong foothold in the Indian
pharmaceutical industry. The company boasts of its ability to deliver
both western and eastern varieties of quality treatments.
$119.09 mn
R
E
V
E
N
U
E
2
I
N
D
I
A
32
ARVIND REMEDIES
Chairman:
Mr Mannalal B Agrawal
Website: www.ajantapharma.com
Start-up Year: 1973
I
N
D
I
A
This Indian specialty pharmaceutical company is
engaged in the development, manufacture and commercialization of
pharmaceutical products. The company pioneers in synergistic com-
bination products in the therapeutic areas of anti-malarial, cardiology,
dermatology, gastroenterology, musculoskeletal, ophthalmology and re-
spiratory. Its undivided focus on specialty segments in India and simul-
taneous opening of new international markets have ensured its growth.
R
E
V
E
N
U
E
$153.17 mn
AJANTA PHARMA
31
CEO:
Mr HyungTae, Kim
Website: www.macrogen.com
Start-up Year: 1997
Macrogen provides DNA sequencing and genome
research services, and also raises and sells transgenic and knockout
mice to biotechnology institutes and pharmaceutical companies. Mac-
rogen develops DNA chips, which are used to improve the diagnosis
and treatment of disease as well. Among other services, Macrogen of-
fers sequencing services for base sequence analysis of plasmid and PCR
product, 16S rDNA sequencing, and sequencing of DNA templates.
$39. 72 mn
R
E
V
E
N
U
E
2 34
MACROGEN
CEO & MD:
Mr Prakash M Patil
Website: www.aartidrugs.co.in
Start-up Year: 1984
I
N
D
I
A
Aarti Drugs has established a strong presence in
the anti-diarrhea and anti-infammatory therapeutic groups of drugs.
It manufactures vitamins, anti-arthritis, anti-fungal, antibiotics, ACE
inhibitors, along with anti-diabetic, anti-cholinergic, sedatives, and
anti-depressant drugs. The company is also in the process of acquir-
ing an ISO 9002 compliance for all its units and one of the units has
already been approved.
R
E
V
E
N
U
E
$161. 29 mn
AARTI DRUGS
33
Executive chairman:
Mr Richard Treagus
Website: www.neurenpharma.com
This dynamic biopharmaceutical company devel-
ops human therapies for neuroprotection and metabolic related disor-
ders. Its drugs target acute indications of brain injury such as traumat-
ic brain injury, as well as chronic conditions such as Parkinsons and
Alzheimers diseases. Neuren is also engaged in research and develop-
ment in metabolic disorders such as cancers related to the functions of
growth hormone.
R
E
V
E
N
U
E
$4.50 mn
NEUREN PHARMACEUTICALS
35
N
E
W

Z
E
A
L
A
N
D

/

A
U
S
T
R
A
L
I
A
38%
38%
36%
36%
36%
B
i
o
S
p
e
c
t
r
u
m

A
s
i
a

F
a
s
t
e
s
t

5
0

L
i
s
t

2
0
1
3
SIHUAN PHARMACEUTICAL COMPANY
S
O
U
T
H

K
O
R
E
A
A CyberMedia Publication | www.BioSpectrumAsia.com | BioSpectrum 10
Chairman & CEO:
Dr Che Fengsheng
Website: www.sihuanpharm.com
Start-up Year: 2001
In merely 11 years, this company has grown to be-
come the ninth biggest pharmaceutical company in Chinas prescrip-
tion drug market. Sihuan is also the largest cardio-cerebral vascular
prescription drug franchise by market share. The companys product
portfolio comprises proprietary products that encompass all the fve
medical therapeutic areas in China: cardio-cerebral vascular system,
central nervous system, metabolism, oncology and anti-infectives.
$486.80 mn
R
E
V
E
N
U
E
2
C
H
I
N
A
37
SIHUAN PHARMACEUTICAL COMPANY
Chairman & MD:
Mr Glenn Saldanha
Website: www.glenmarkpharma.com
Start-up Year: 2000
I
N
D
I
A
This company has signifcant presence in the
branded generics markets across many emerging economies. It is a
leading player in the discovery of new molecules, both NCEs (new
chemical entity) and NBEs (new biological entity), with fve molecules
in various stages of clinical development. Glenmark ranks among
worlds top pharma and biotech companies, and has 13 manufacturing
facilities in four countries and fve R&D centers.
R
E
V
E
N
U
E
$383.94 mn
GLENMARK PHARMACEUTICALS
36
Chairman & director:
Mr Michael G Daniell
Website: www.fphcare.com
Start-up Year: 1971
Fisher & Paykel manufactures, designs and mar-
kets products and systems for use in respiratory care, acute care, and
the treatment of obstructive sleep apnoea. It focuses on respiratory
and acute care respiratory humidifers, single-use and reusable cham-
bers and breathing circuits, and sells its products in 120 countries. Its
neonatal care products include infant warmers, infant resuscitators
and CPAP systems to improve infant respiratory function.
$548.07 mn
R
E
V
E
N
U
E
2
A
U
S
T
R
A
L
I
A
39
FISHER & PAYKEL HEALTHCARE
Group President:
Mr Shakti Chakraborty
Website: www.lupinworld.com
Start-up Year: 1968
I
N
D
I
A
Recognized for becoming one of the worlds largest
manufacturers of tuberculosis drugs, the company today is the seventh
largest Indian domestic formulations major in the Indian pharmaceu-
tical market. Lupin boasts of holding a signifcant market share in key
markets in the cardiovascular, diabetology, asthma, pediatrics, CNS,
GI, anti-infectives and NSAIDs therapy segments along with being the
global leaders in anti-TB and cephalosporins segments.
R
E
V
E
N
U
E
$1395.47 mn
LUPIN
38
Chairman:
Mr Jagdish K Shah
Website: www.aareydrugs.com
Start-up Year: 1990
I
N
D
I
A
Aarey Drugs is increasingly growing popular for
being manufacturer representatives and suppliers of pharmaceutical
raw materials, chemicals, pharmaceuticals ingredients, API drugs,
and food colors and favors. Currently, the company is working on the
manufacturing of Metronidazole and Metronidazole Benzoate. The
company is soon planning to introduce two new products and is diver-
sifying in development of drug intermediates.
R
E
V
E
N
U
E
$32.50 mn
AAREY DRUGS
40
36%
36%
36%
36%
36%
Fastest 50
B
i
o
S
p
e
c
t
r
u
m

A
s
i
a

F
a
s
t
e
s
t

5
0

L
i
s
t

2
0
1
3
11 BioSpectrum | www.BioSpectrumAsia.com | A CyberMedia Publication
Fastest 50
MD & chairman:
Dr Aditya Narayan Singh
Website: www.celestiallabs.com
Start-up Year: 1997
The company has three decades of experience in
drug discovery using Insilico process. Currently, the company is en-
gaged in biopharmaceutical formulations, consisting of herbal, nutra-
ceuticals and enzyme formulations. The company has prioritized the
development of 4C Peptide through a biological route for the treat-
ment of Vitiligo, tanning and ant wrinkles. It also plans to venture into
the online marketing of natural products
$5.10 mn
R
E
V
E
N
U
E
2
I
N
D
I
A
42
CELESTIAL BIOLABS
CEO:
Mr Douglas Godshall
Website: www.heartware.com
A
U
S
T
R
A
L
I
A
This medical devices company develops a family of
implantable Left Ventricular Assist Devices (LVADs) for the treatment
of advanced heart failure. It delivers safe, high performing and trans-
formative therapies that enable patients with heart failure to get back
to life. The companys innovative technologies are creating advances
in the miniaturization of Ventricular Assist Devices (VADs) leading to
less invasive surgical procedures.
R
E
V
E
N
U
E
$110.90 mn
HEARTWARE
41
Chairman, president & CEO:
Chan Chi-Hsien
Website: www.adimmune.com.tw
Start-up Year: 1965
With over 45 years of expertise in vaccinology, Ad-
immune engages in the development, manufacture, and distribution of
human vaccines in Taiwan. The companys primary products include
seasonal infuenza vaccine, AdimFlu-s (A/H1N1), Japanese encephali-
tis vaccine, and tetanus toxoid alum precipitated, as well as tuberculin
purifed protein derivative for mantoux testing. Currently, it is looking
at preparing a vaccine for H7N9 avian infuenza.
$11.62 mn
R
E
V
E
N
U
E
2
T
A
I
W
A
N
44
ADIMMUNE
Chairman: Mr Zhao Yan
Website:
www.bloomagebio-tech.com
Start-up Year: 2006
C
H
I
N
A
Abiding by the companys motto Open stream
delivers excellence, the company has become the market leader in
producing hyaluronic acid (HA) that is used in medical, cosmetic, and
food products. HA, the key product of this company, is a kind of gly-
cosaminoglycans used mainly in pharmaceutical products, cosmetics
and health supplement. The US, Japan, the European Union, Canada,
Brazil, Korea and Taiwan are its leading markets.
R
E
V
E
N
U
E
$44 mn
BLOOMAGE BIOTECHNOLOGY
43
Chairman/President:
Mr Chen Le-Wei
Website: www.sagittarius.com.tw
Start-up Year: 1998
T
A
I
W
A
N
The company develops a wide range of Chinese
herbal medicines and supplements. The companys products include
SO101C, an anti-ageing agent for the prevention and treatment of
bone fractures and osteoporosis; ST104P, an anti-angiogenesis agent;
ST188L, the immune booster; SA201D, a transdermal patch for Al-
zheimers disease; SA103T, an anti-osteoarthritis agent; and SS102T,
a wound healing and skin care agent.
R
E
V
E
N
U
E
$11.34 mn
SAGITTARIUS LIFE SCIENCE
45
B
i
o
S
p
e
c
t
r
u
m

A
s
i
a

F
a
s
t
e
s
t

5
0

L
i
s
t

2
0
1
3
34%
34%
33%
33%
33%
A CyberMedia Publication | www.BioSpectrumAsia.com | BioSpectrum 12
Chairman:
Dr C Nageswara Rao
Website: www.granulesindia.com
Start-up Year: 1984
Granules India manufactures Finished Dosages
(Fds), Pharmaceutical Formulation Intermediates (PFIs) and APIs
that are distributed across 50 countries. The company also manufac-
tures several off-patent drugs, including Paracetamol, Ibuprofen, Met-
formin and Guaifenesin, on a large scale for customers in the regulated
and semi-regulated markets. Granules exports mainly to developed
markets like the US, Europe, Mexico and Hong Kong.
$133.25 mn
R
E
V
E
N
U
E
2
I
N
D
I
A
47
GRANULES INDIA
Board Chairman:
Mr She Lulin
Website: www.sinopharm.com
Start-up Year: 1998
C
H
I
N
A
With operations in Africa, France, Germany, Hong
Kong, the US and Vietnam, today Sinopharm is Chinas largest phar-
maceutical company. It is jointly owned by China National Pharmaceu-
tical and Shanghai Fosun Pharmaceutical. The company researches,
develops, manufactures, distributes, and markets medicine and other
healthcare products through its three main segments - pharmaceutical
distribution, retail pharmacy, and other business.
R
E
V
E
N
U
E
$21.17 bn
SINOPHARM
46
Chairman:
Mr Sudhir Mehta
Website: www.torrentpharma.com
Start-up Year: 1970
The company focuses on formulations, API, drug
discovery, marketing and sales of drugs. Torrent has dominated the
market of therapeutic areas of cardiovascular (CV) and central ner-
vous system (CNS) and has achieved signifcant presence in gastro-
intestinal, diabetology, anti-infective and pain management segments.
Torrent Pharma, through its subsidiaries, plans to make an entry into
several regulated and less regulated international markets.
$513.62 mn
R
E
V
E
N
U
E
2
I
N
D
I
A
49
TORRENT PHARMA
CEO:
Jong-Yoon Cheon
Website: www.seegene.com
Start-up Year: 2000
This company specializes in molecular diagnos-
tics and develops technology and products that diagnose disease from
the genetic level. So far, the company has various molecular diagno-
sis products that are developed in-house including simultaneous and
multiple detection technologies (Acp, Dpo, Read, Toce). Seegenes in-
novate technology allows testing of multiple pathogens with one single
test, thereby minimizing testing time and cost.
R
E
V
E
N
U
E
$46.30 mn
SEEGENE
48
Chairman & MD:
Mr Murali K Divi
Website: www.divislabs.com
Start-up Year: 1990
I
N
D
I
A
The company was established to primarily con-
duct research and development of new processes for the production of
APIs and intermediates. Soon the company expanded to provide com-
plete turnkey solutions to the Indian pharmaceutical industry. Divis is
involved in developing alternate, patent non-infringing processes for
APIs, for the inventors to manage late life cycle and leading generic
drug manufacturers.
R
E
V
E
N
U
E
$437. 81 mn
DIVIS LABORATORIES
50
B
i
o
S
p
e
c
t
r
u
m

A
s
i
a

F
a
s
t
e
s
t

5
0

L
i
s
t

2
0
1
3
S
O
U
T
H

K
O
R
E
A
33%
32%
30%
30%
30%
Fastest 50